TIMP-2 modulates VEGFR-2 phosphorylation and enhances phosphodiesterase activity in endothelial cells

Laboratory Investigation

Volumn 90, Issue 3, 2010, Pages 374-382

  Lee, Seo Jin ^a,b   Tsang, Patricia S ^a   M Diaz, Tere ^a   Wei, Bei Yang ^a   Stetler Stevenson, William George ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Shingyeong University   (South Korea)

Author keywords

Angiogenesis; Endothelial cells; Phosphodiesterase; Protein tyrosine phosphatase; Tissue inhibitors of metalloproteinases

Indexed keywords

CALCIUM; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ISOBUTYLMETHYLXANTHINE; PHOSPHODIESTERASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; HUMAN CELL; MITOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

1-METHYL-3-ISOBUTYLXANTHINE; CALCIUM; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CYCLIC GMP; ENDOTHELIAL CELLS; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HUMANS; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHOLIPASE C GAMMA; PHOSPHORIC DIESTER HYDROLASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77649143135     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2009.136     Document Type: Article

References (36)

1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
2. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-744.
3. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003;3:422-433.
4. Doggrell SA. Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration. Expert Opin Pharmacother 2005;6:1421-1423.
5. Jain RK, Duda DG, Clark JW, et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40.
6. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-248.
7. Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359-371.
8. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metallo-proteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267-283.
9. Fernandez CA, Butterfield C, Jackson G, et al. Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor. J Biol Chem 2003;278:40989-40995.
10. Seo DW, Kim SH, Eom SH, et al. TIMP-2 disrupts FGF-2-induced downstream signaling pathways. Microvasc Res 2008;76:145-151.
11. Seo DW, Li H, Guedez L, et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003;114: 171-180.
12. Seo DW, Li H, Qu CK, et al. Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells. J Biol Chem 2006;281:3711-3721.
13. Shultz LD, Schweitzer PA, Rajan TV, et al. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 1993;73:1445-1454.
14. Oh J, Diaz T, Wei B, et al. TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118. Oncogene 2006;25:4230-4234.
15. Wingfield PT, Sax JK, Stahl SJ, et al. Biophysical and functional characterization of full-length, recombinant human tissue inhibitor of metalloproteinases-2 (TIMP-2) produced in Escherichia coli. Comparison of wild type and amino-terminal alanine appended variant with implications for the mechanism of TIMP functions. J Biol Chem 1999;274:21362-21368.
16. Lee JS, Kang Decker N, Chatterjee S, et al. Mechanisms of nitric oxide interplay with Rho GTPase family members in modulation of actin membrane dynamics in pericytes and fibroblasts. Am J Pathol 2005;166:1861-1870.
17. Saini R, Patel S, Saluja R, et al. Nitric oxide synthase localization in the rat neutrophils: immunocytochemical, molecular, and biochemical studies. J Leukoc Biol 2006;79:519-528.
18. Guo D, Tan YC, Wang D, et al. A Rac-cGMP signaling pathway. Cell 2007;128:341-355.
19. Dougher M, Terman BI. Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene 1999;18:1619-1627.
20. Poulin B, Sekiya F, Rhee SG. Intramolecular interaction between phosphorylated tyrosine-783 and the C-terminal Src homology 2 domain activates phospholipase C-gamma1. Proc Natl Acad Sci USA 2005;102:4276-4281.
21. Takahashi T, Yamaguchi S, Chida K, et al. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. Embo J 2001;20:2768-2778.
22. DeBell K, Graham L, Reischl I, et al. Intramolecular regulation of phospholipase C-gamma1 by its C-terminal Src homology 2 domain. Mol Cell Biol 2007;27:854-863.
23. Holmqvist K, Cross MJ, Rolny C, et al. The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem 2004;279:22267-22275.
24. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-1101.
25. Busse R, Mulsch A. Calcium-dependent nitric oxide synthesis in endothelial cytosol is mediated by calmodulin. FEBS Lett 1990;265:133-136.
26. Dimmeler S, Fleming I, Fisslthaler B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999;399:601-605.
27. Stone JR, Marletta MA. Soluble guanylate cyclase from bovine lung: activation with nitric oxide and carbon monoxide and spectral characterization of the ferrous and ferric states. Biochemistry 1994;33:5636-5640.
28. Oh J, Seo DW, Diaz T, Wei B, Ward Y, Ray JM, et al. Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK. Cancer Res 2004;64:9062-9069.
29. Fleming I, Fisslthaler B, Dimmeler S, et al. Phosphorylation of Thr (495) regulates Ca(2+)/calmodulin-dependnet endothelilal nitic oxide synthetase activity. Circ Res 2001;88:E68-E75.
30. Isenberg JS, Ridnour LA, Perruccio EM, et al. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci USA 2005;102:13141-13146.
31. Hoegy SE, Oh HR, Corcoran ML, et al. Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition. J Biol Chem 2001;276:3203-3214.
32. Corcoran ML, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism. J Biol Chem 1995;270:13453-13459.
33. DeFouw LM, DeFouw DO. Differential phosphodiesterase activity contributes to restrictive endothelial barrier function during angiogenesis. Microvasc Res 2001;62:263-270.
34. Matsumoto T, Bohman S, Dixelius J, et al. VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. Embo J 2005;24:2342-2353.
35. Ahmad S, Hewett PW, Wang P, et al. Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ Res 2006;99:715-722.
36. Bhattacharya R, Kwon J, Wang E, et al. Src homology 2 (SH2) domain containing protein tyrosine phosphatase-1 (SHP-1) dephosphorylates VEGF Receptor-2 and attenuates endothelial DNA synthesis, but not migration. J Mol Signal 2008;3:8-20.